长江医药控股股份有限公司 (Changjiang Pharmaceutical Holdings Co., Ltd.) Announcement on the Fourth Risk Warning for the Company's Stock Entering the Delisting Arrangement Period
The Company and the entire Board of Directors guarantee that the information disclosed is true, accurate, and complete, and contains no false records, misleading statements, or significant omissions.
Special Reminder:
- The shares of Changjiang Pharmaceutical Holdings Co., Ltd. (hereinafter referred to as the "Company") will be delisted on the next trading day after the delisting arrangement period ends, and the Company's shares will be terminated from listing.
- The Company's shares entered the delisting arrangement period on March 20, 2026. The delisting arrangement period is fifteen trading days, and the expected last trading day is April 10, 2026. The disclosure date of this announcement (April 3, 2026) is the eleventh trading day. There are four remaining trading days. After the period expires, the listing will be terminated. Investors are urged to invest prudently and be aware of the risks.
- During the trading period of the Company's shares in the delisting arrangement period, the Company will not plan or implement any major asset restructuring.
- Investors, securities companies, and other market participants are requested to promptly settle stock pledge repurchase, agreed repurchase, margin financing, securities lending, and other businesses before the stock is delisted.
- For judicial freezing businesses that expire after the stock is delisted and before the initial registration period of the two-network company and delisted company segment managed by Shenzhen Securities Information Technology Co., Ltd. on behalf of the original securities company, it is recommended that the competent authorities handle the renewal of freezing procedures in advance through the original execution channels before the stock is delisted.